After years of weight loss drug shortages, the FDA is saying there's now an adequate supply for most medications and they ...

In moderate to severe pain from blunt trauma, sublingual sufentanil was not more effective than standard care in reducing pain at 30 minutes.

Compliant offerings include: GLP-1s (semaglutide, tirzepatide), peptides, personalized healthcare treatments, sermorelin, testosterone replacement therapy (“TRT”), hair loss, skincare, sexual health ...

VANCOUVER, British Columbia and LAS VEGAS, Feb. 27, 2025 (GLOBE NEWSWIRE) -- Hydreight Technologies Inc. (“Hydreight” or the “Company”) (TSXV: NURS) (OTCQB ...

sublingual, capsule, and tablet. This expansion strengthens Hydreight’s leadership in telehealth innovation while positioning the company to participate in the booming global weight loss market.

Semaglutide formulation for a sublingual semaglutide product is nearly complete; FDA approval process to start in late 2025. Early studies of migraine rapid relief product to be delivered via Aspire's ...

Semaglutide formulation for a sublingual semaglutide product is nearly complete; FDA approval process to start in late 2025. Early studies of migraine rapid relief product to be delivered via ...

Compounders have been permitted to manufacture copycat versions of Novo’s semaglutide and Lilly’s tirzepatide since 2022 when the FDA declared that both were in shortage. In October ...

This legal move, initiated by the Outsourcing Facilities Association and others in a Fort Worth, Texas federal court, argues that the FDA's ruling, which states no existing shortage of the active ...

Semaglutide formulation for a sublingual semaglutide product is nearly complete; FDA approval process to start in late 2025. Early studies of migraine rapid relief product to be delivered via ...